Sanjiv J Shah

List of Publications by Year in Descending Order

420 papers	20,057 citations	70 h-index	129 g-index
461 ext. papers	27,472 ext. citations	7.8 avg, IF	6.98 L-index

#	Paper	IF	Citations
420	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management.. *Heart*, **2022**,	5.1	10
419	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.. *JACC: Heart Failure*, **2022**, 10, 129-138	7.9	0
418	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.. *Lancet, The*, **2022**,	40	12
417	Genetic variation in sodium glucose co-transporter 1 and cardiac structure and function at middle age.. *ESC Heart Failure*, **2022**,	3.7	1
416	Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 804788	5.4	0
415	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.. *Circulation*, **2022**,	16.7	7
414	Immunometabolic mechanisms of heart failure with preserved ejection fraction **2022**, 1, 211-222		3
413	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. *JACC: Heart Failure*, **2022**, 10, 184-197	7.9	4
412	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. *JACC: Heart Failure*, **2022**, 10, 336-346	7.9	0
411	Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018.. *Circulation: Heart Failure*, **2022**, CIRCHEARTFAILURE121009351	7.6	
410	Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction.. *Heart Failure Clinics*, **2022**, 18, 287-300	3.3	0
409	Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week.. *Journal of the American College of Cardiology*, **2022**, 79, 1858-1869	15.1	2
408	Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.. *Circulation Research*, **2022**, 130, 1382-1403	15.7	1
407	Development and Validation of A Long-Term Incident Heart Failure Risk Model. *Circulation Research* , **2021**,	15.7	1
406	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.. *Circulation: Heart Failure*, **2021**, CIRCHEARTFAILURE120008193	7.6	9
405	Risk Marker Fatigue-Is There an Actionable Outcome?. *JAMA Cardiology*, **2021**, 6, 78	16.2	
404	The association between indices of blood pressure waveforms (PTC1 and PTC2) and incident heart failure. *Journal of Hypertension*, **2021**, 39, 661-666	1.9	3

403	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1919-1929	27.4	10
402	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation*, **2021**,	16.7	12
401	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 785109	5.4	0
400	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. *JACC: CardioOncology*, **2021**, 3, 537-546	3.8	3
399	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2021**, 14, e008293	7.6	2
398	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nature Medicine*, **2021**, 27, 1954-1960	50.5	29
397	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. *Hypertension*, **2021**, 78, 1742-1749	8.5	0
396	Misfolded Transthyretin as a Novel Risk Factor for Heart Failure: A Rich History With Implications for Future Diagnosis and Treatment. *JAMA Cardiology*, **2021**, 6, 255-257	16.2	
395	Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes. *Journal of the American Heart Association*, **2021**, 10, e019519	6	3
394	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. *Journal of the American College of Cardiology*, **2021**, 77, 1211-1221	15.1	1
393	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. *Scientific Reports*, **2021**, 11, 4885	4.9	8
392	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. *European Journal of Heart Failure*, **2021**, 23, 754-764	12.3	3
391	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. *Circulation*, **2021**, 143, 949-958	16.7	2
390	Age dependent associations of risk factors with heart failure: pooled population based cohort study. *BMJ, The*, **2021**, 372, n461	5.9	11
389	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. *American Journal of Medicine*, **2021**, 134, e153-e164	2.4	6
388	Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA). *Biomarkers*, **2021**, 26, 309-317	2.6	0
387	Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets. *Current Heart Failure Reports*, **2021**, 18, 85-98	2.8	4
386	Role of t-tubule remodeling on mechanisms of abnormal calcium release during heart failure development in canine ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2021**, 320, H1658-H1669	5.2	2

385	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. *Journal of the American Society of Echocardiography*, **2021**, 34, 455-464	5.8	0
384	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. *Journal of Cardiac Failure*, **2021**, 27, 1214-1221	3.3	
383	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. *JACC: Heart Failure*, **2021**, 9, 386-397	7.9	2
382	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial. *JACC: Heart Failure*, **2021**, 9, 360-370	7.9	16
381	A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. *Nature Communications*, **2021**, 12, 2725	17.4	16
380	Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. *Nature Communications*, **2021**, 12, 2726	17.4	18
379	Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction. *ESC Heart Failure*, **2021**, 8, 2535-2545	3.7	9
378	Association Between Myocardial Strain and Frailty in CHS. *Circulation: Cardiovascular Imaging*, **2021**, 14, e012116	3.9	1
377	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *European Journal of Heart Failure*, **2021**, 23, 1217-1225	12.3	39
376	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1472-1487	10.2	13
375	Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. *Hypertension*, **2021**, 77, 2023-2033	8.5	0
374	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000029	3.9	12
373	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1. *JAMA Cardiology*, **2021**, 6, 841-846	16.2	2
372	Associations of Cardiac Mechanics With Exercise Capacity: The Multi-Ethnic Study of Atherosclerosis. *Journal of the American College of Cardiology*, **2021**, 78, 245-257	15.1	6
371	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000030	3.9	6
370	Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. *Bone Marrow Transplantation*, **2021**, 56, 50-59	4.4	7
369	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. *Journal of Cardiac Failure*, **2021**, 27, 309-317	3.3	2
368	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. *Journal of Cardiac Failure*, **2021**, 27, 435-444	3.3	2

367	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. *Journal of the American Geriatrics Society*, **2021**, 69, 1309-1318	5.6	2
366	Role of PAI-1 in hepatic steatosis and dyslipidemia. *Scientific Reports*, **2021**, 11, 430	4.9	6
365	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. *ESC Heart Failure*, **2021**, 8, 1482-1493	3.7	4
364	Risk-Based Approach for the Prediction and Prevention of Heart Failure. *Circulation: Heart Failure*, **2021**, 14, e007761	7.6	3
363	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. *Hypertension*, **2021**, 77, 546-556	8.5	7
362	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. *European Journal of Heart Failure*, **2021**, 23, 776-784	12.3	3
361	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. *Circulation: Heart Failure*, **2021**, 14, e008090	7.6	2
360	Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. *ESC Heart Failure*, **2021**, 8, 2089-2102	3.7	9
359	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2021**,	3.3	1
358	Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2021**, 23, 1541-1551	12.3	7
357	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. *Journal of Cardiac Failure*, **2021**, 27, 816-818	3.3	
356	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. *Journal of Nuclear Cardiology*, **2021**, 28, 1769-1774	2.1	4
355	Generalizability of HFA-PEFF and HFPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. *Journal of Cardiac Failure*, **2021**, 27, 756-765	3.3	5
354	Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. *Journal of the American Heart Association*, **2021**, 10, e020499	6	2
353	Associations of body size and composition with subclinical cardiac dysfunction in older individuals: the cardiovascular health study. *International Journal of Obesity*, **2021**, 45, 2539-2545	5.5	0
352	Cardiac mechanics and incident ischemic stroke: the Cardiovascular Health Study. *Scientific Reports*, **2021**, 11, 17358	4.9	4
351	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. *ESC Heart Failure*, **2021**, 8, 3495-3503	3.7	1
350	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. *Journal of the American Heart Association*, **2021**, 10, e019545	6	3

349	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 1166-1187	15.1	17
348	Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial. *Journal of Cardiac Failure*, **2021**, 27, 1023-1026	3.3	6
347	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. *Circulation: Heart Failure*, **2021**, 14, e008354	7.6	7
346	Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. *JACC: Heart Failure*, **2021**, 9, 795-802	7.9	3
345	Risk Markers for Limited Coronary Artery Calcium in Persons With Significant Aortic Valve Calcium (From the Multi-ethnic Study of Atherosclerosis). *American Journal of Cardiology*, **2021**, 156, 58-64	3	2
344	Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure. *Heart Failure Clinics*, **2020**, 16, 387-407	3.3	6
343	Genetic-Based Hypertension Subtype Identification Using Informative SNPs. *Genes*, **2020**, 11,	4.2	2
342	Fibroblast Growth Factor 23 and Long-Term Cardiac Function: The Multi-Ethnic Study of Atherosclerosis. *Circulation: Cardiovascular Imaging*, **2020**, 13, e011925	3.9	7
341	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. *ESC Heart Failure*, **2020**, 7, 1676-1687	3.7	5
340	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. *JACC: Heart Failure*, **2020**, 8, 618-626	7.9	6
339	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. *Circulation*, **2020**, 142, 230-243	16.7	19
338	Cellular Adhesion Molecules in Young Adulthood and Cardiac Function in Later Life. *Journal of the American College of Cardiology*, **2020**, 75, 2156-2165	15.1	13
337	Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. *European Journal of Heart Failure*, **2020**, 22, 1009-1018	12.3	48
336	Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes. *ESC Heart Failure*, **2020**, 7, 811-824	3.7	5
335	Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. *Circulation*, **2020**, 141, 1001-1026	16.7	95
334	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. *European Journal of Heart Failure*, **2020**, 22, 1675-1683	12.3	10
333	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. *JACC: Heart Failure*, **2020**, 8, 372-381	7.9	25
332	Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. *JAMA Cardiology*, **2020**, 5, 497-499	16.2	17

331	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. *ESC Heart Failure*, **2020**, 7, 1956-1965	3.7	17
330	Embarking upon atrial fibrillation management in heart failure with preserved ejection fraction: Charting a course. *Journal of Cardiovascular Electrophysiology*, **2020**, 31, 2284-2287	2.7	1
329	Coronary Microvascular Dysfunction in HIV: A Review. *Journal of the American Heart Association*, **2020**, 9, e014018	6	8
328	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. *Circulation*, **2020**, 141, 1214-1224	16.7	69
327	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. *Heart*, **2020**, 106, 342-349	5.1	38
326	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). *American Heart Journal*, **2020**, 222, 183-190	4.9	10
325	Heart Failure with Preserved Ejection Fraction and Obesity: Syndrome of cGMP-PKG Deficiency in Post-Menopausal Women. *JACC: Case Reports*, **2020**, 2, 28-32	1.2	1
324	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. *Journal of Cardiac Failure*, **2020**, 26, 233-242	3.3	4
323	Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study. *Journal of the American Heart Association*, **2020**, 9, e013966	6	7
322	Differential Associations of Chronic Inflammatory Diseases With Incident Heart Failure. *JACC: Heart Failure*, **2020**, 8, 489-498	7.9	22
321	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. *Journal of the American Heart Association*, **2020**, 9, e014279	6	35
320	Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study. *JCI Insight*, **2020**, 5,	9.9	16
319	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. *PLoS ONE*, **2020**, 15, e0240567	3.7	3
318	Association of the HFPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. *Journal of Atrial Fibrillation*, **2020**, 12, 2295	0.8	3
317	Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Cardiology*, **2020**, 5, 184-192	16.2	8
316	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. *Journal of Cardiac Failure*, **2020**, 26, 371-380	3.3	10
315	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. *European Journal of Heart Failure*, **2020**, 22, 557-559	12.3	3
314	Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study. *Journal of the American Academy of Dermatology*, **2020**, 83, 1647-1653	4.5	9

313	Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2020**, 22, 413-421	12.3	44
312	Polygenic Risk, Fitness, and Obesity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Cardiology*, **2020**, 5, 40-48	16.2	6
311	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *European Journal of Heart Failure*, **2020**, 22, 472-485	12.3	28
310	Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. *ESC Heart Failure*, **2020**, 7, 253-263	3.7	27
309	Associations of awake and asleep blood pressure and blood pressure dipping with abnormalities of cardiac structure: the Coronary Artery Risk Development in Young Adults study. *Journal of Hypertension*, **2020**, 38, 102-110	1.9	8
308	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. *Journal of Cardiac Failure*, **2020**, 26, 270-275	3.3	6
307	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. *Circulation*, **2020**, 141, 338-351	16.7	122
306	Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). *American Heart Journal*, **2020**, 226, 222-231	4.9	10
305	Preoperative left atrial strain abnormalities are associated with the development of postoperative atrial fibrillation following isolated coronary artery bypass surgery. *Journal of Thoracic and Cardiovascular Surgery*, **2020**,	1.5	8
304	COVID-19 and Heart Failure With Preserved Ejection Fraction. *JAMA - Journal of the American Medical Association*, **2020**, 324, 1499-1500	27.4	43
303	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 1512-1521	27.4	71
302	Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 1522-1531	27.4	39
301	Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". *Circulation*, **2020**, 142, e212-e213	16.7	1
300	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. *Circulation: Heart Failure*, **2020**, 13, e007462	7.6	5
299	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. *Circulation*, **2020**, 142, 2029-2044	16.7	32
298	Relation of Biomarkers of Cardiac Injury, Stress, and Fibrosis With Cardiac Mechanics in Patients 65 Years of Age. *American Journal of Cardiology*, **2020**, 136, 156-163	3	2
297	Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. *JACC: Heart Failure*, **2020**, 8, 712-724	7.9	58
296	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. *Digital Biomarkers*, **2020**, 4, 45-59	7.1	6

295	Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). *Journal of the American Heart Association*, **2020**, 9, e019390	6	13
294	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. *Journal of the American College of Cardiology*, **2020**, 76, 503-514	15.1	27
293	Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. *Journal of Cardiac Failure*, **2020**, 26, 919-928	3.3	1
292	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. *Journal of Cardiac Failure*, **2020**, 26, 1016-1021	3.3	9
291	The Upcoming Epidemic of Heart Failure in South Asia. *Circulation: Heart Failure*, **2020**, 13, e007218	7.6	10
290	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. *Journal of the American College of Cardiology*, **2020**, 76, 1455-1465	15.1	15
289	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. *Journal of the American Heart Association*, **2020**, 9, e016760	6	9
288	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Cardiology*, **2020**,	16.2	1
287	Association of liver stiffness and cardiovascular outcomes in patients with heart failure: A systematic review and meta-analysis. *European Journal of Preventive Cardiology*, **2020**, 27, 331-334	3.9	6
286	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. *Journal of Cardiac Failure*, **2020**, 26, 101-107	3.3	14
285	Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. *ESC Heart Failure*, **2020**, 7, 856-864	3.7	22
284	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure **2020**, 15, e0240567		
283	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure **2020**, 15, e0240567		
282	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure **2020**, 15, e0240567		
281	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure **2020**, 15, e0240567		
280	Ankle-brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis. *Vascular Medicine*, **2019**, 24, 501-510	3.3	5
279	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*, **2019**, 381, 1609-1620	59.2	705
278	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Journal of Cardiac Failure*, **2019**, 25, 854-865	3.3	40

277	Coronary Microvascular Dysfunction and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. *Journal of Cardiac Failure*, **2019**, 25, 843-845	3.3	5
276	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2019**, 25, e1-e39	3.3	56
275	Prevalence of American Heart Association Heart Failure Stages in Black and White Young and Middle-Aged Adults: The CARDIA Study. *Circulation: Heart Failure*, **2019**, 12, e005730	7.6	10
274	Parent-of-origin effects on quantitative phenotypes in a large Hutterite pedigree. *Communications Biology*, **2019**, 2, 28	6.7	8
273	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. *Trends in Molecular Medicine*, **2019**, 25, 328-340	11.5	23
272	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2019**, 12, e006125	7.6	10
271	Rationale and Design of the VITALITY-HFpEF Trial. *Circulation: Heart Failure*, **2019**, 12, e005998	7.6	22
270	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2019**, 321, 2101-2112	27.4	29
269	10-Year Risk Equations for Incident Heart Failure in the General Population. *Journal of the American College of Cardiology*, **2019**, 73, 2388-2397	15.1	48
268	Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2019**, 73, 2106-2116	15.1	79
267	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. *JACC: Heart Failure*, **2019**, 7, 321-332	7.9	22
266	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. *Current Treatment Options in Cardiovascular Medicine*, **2019**, 21, 20	2.1	19
265	Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates-Reply. *JAMA Cardiology*, **2019**, 4, 299-300	16.2	0
264	Elevated Plasma Ceramides Are Associated With Antiretroviral Therapy Use and Progression of Carotid Artery Atherosclerosis in HIV Infection. *Circulation*, **2019**, 139, 2003-2011	16.7	21
263	Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. *European Journal of Preventive Cardiology*, **2019**, 26, 1680-1682	3.9	6
262	Myocardial Strain in the Assessment of Patients With Heart Failure: A Review. *JAMA Cardiology*, **2019**, 4, 287-294	16.2	45
261	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). *American Journal of Cardiology*, **2019**, 123, 1660-1666	3	4
260	Clinical correlates and heritability of cardiac mechanics: The HyperGEN study. *International Journal of Cardiology*, **2019**, 274, 208-213	3.2	0

259	Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e00788	2.3	3
258	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. *Journal of the American College of Cardiology*, **2019**, 74, 285-295	15.1	108
257	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. *JACC: Heart Failure*, **2019**, 7, 664-675	7.9	28
256	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. *Mayo Clinic Proceedings*, **2019**, 94, 1199-1209	6.4	35
255	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. *European Journal of Heart Failure*, **2019**, 21, 1288-1291	12.3	11
254	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. *Circulation*, **2019**, 140, 1359-1361	16.7	4
253	Association of Lipidomic Profiles With Progression of Carotid Artery Atherosclerosis in HIV Infection. *JAMA Cardiology*, **2019**, 4, 1239-1249	16.2	16
252	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). *American Journal of Cardiology*, **2019**, 124, 1912-1917	3	10
251	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology. *Journal of the American Society of Echocardiography*, **2019**, 32, 1379-1395.e2	5.8	6
250	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. *Journal of the American College of Cardiology*, **2019**, 74, 2539-2550	15.1	40
249	Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA. *Journal of the American Heart Association*, **2019**, 8, e013149	6	10
248	The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. *Current Opinion in Supportive and Palliative Care*, **2019**, 13, 24-30	2.6	7
247	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. *Journal of the American College of Cardiology*, **2019**, 74, 2858-2873	15.1	55
246	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. *JACC: Heart Failure*, **2019**, 7, 1022-1028	7.9	2
245	Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection. *Aids*, **2019**, 33, 1043-1052	3.5	2
244	Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization. *Bioinformatics*, **2019**, 35, 1395-1403	7.2	6
243	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. *JACC: Heart Failure*, **2019**, 7, 25-32	7.9	32
242	Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans. *Journal of Cardiac Failure*, **2019**, 25, 51-59	3.3	8

241	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. *JACC: Heart Failure*, **2019**, 7, 47-55	7.9	6
240	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. *Annual Review of Pharmacology and Toxicology*, **2019**, 59, 41-63	17.9	15
239	Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis. *American Journal of Hypertension*, **2018**, 31, 774-783	2.3	12
238	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. *Journal of Cardiac Failure*, **2018**, 24, 255-265	3.3	22
237	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. *JACC: Heart Failure*, **2018**, 6, 653-661	7.9	34
236	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. *Circulation: Heart Failure*, **2018**, 11, e004312	7.6	26
235	Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease. *Circulation: Heart Failure*, **2018**, 11, e004436	7.6	51
234	Plasma Tryptophan-Kynurenine Metabolites Are Altered in Human Immunodeficiency Virus Infection and Associated With Progression of Carotid Artery Atherosclerosis. *Clinical Infectious Diseases*, **2018**, 67, 235-242	11.6	28
233	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. *JAMA Cardiology*, **2018**, 3, 215-224	16.2	115
232	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging: Potential Approach to Research and Clinical Practice. *Circulation Research*, **2018**, 122, 23-25	15.7	9
231	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. *Pulmonary Circulation*, **2018**, 8, 2045894018773049	2.7	6
230	Lack of Association Between Heart Failure and Incident Cancer. *Journal of the American College of Cardiology*, **2018**, 71, 1501-1510	15.1	27
229	Population-Based Studies of Invasive Hemodynamics: A Glimpse Into the Future. *JAMA Cardiology*, **2018**, 3, 306-307	16.2	
228	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. *Circulation: Heart Failure*, **2018**, 11, e004457	7.6	20
227	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. *Journal of Cardiac Failure*, **2018**, 24, 313-320	3.3	33
226	Sex differences in vascular dysfunction and cardiovascular outcomes: The cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study. *Hemodialysis International*, **2018**, 22, 93-102	1.7	9
225	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2018**, 20, 16-37	12.3	137
224	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2018**, 20, 815-816	12.3	5

223	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. *European Journal of Heart Failure*, **2018**, 20, 715-722	12.3	26
222	Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. *JACC: Heart Failure*, **2018**, 6, 619-632	7.9	72
221	A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure Rehospitalization. *Journal of Cardiac Failure*, **2018**, 24, 614-617	3.3	6
220	Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. *American Journal of Cardiology*, **2018**, 122, 1359-1365	3	5
219	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. *Circulation: Heart Failure*, **2018**, 11, e004962	7.6	70
218	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. *JACC: Heart Failure*, **2018**, 6, 689-697	7.9	36
217	The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. *JACC: Heart Failure*, **2018**, 6, 701-709	7.9	128
216	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *New England Journal of Medicine*, **2018**, 379, 1007-1016	59.2	859
215	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. *European Heart Journal*, **2018**, 39, 3439-3450	9.5	195
214	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. *JAMA Cardiology*, **2018**, 3, 1000-1005	16.2	24
213	Gut Microbial-Related Choline Metabolite Trimethylamine-N-Oxide Is Associated With Progression of Carotid Artery Atherosclerosis in HIV Infection. *Journal of Infectious Diseases*, **2018**, 218, 1474-1479	7	24
212	Predictors and outcomes of heart failure with mid-range ejection fraction. *European Journal of Heart Failure*, **2018**, 20, 651-659	12.3	46
211	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. *Circulation*, **2018**, 137, 364-375	16.7	140
210	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. *European Journal of Heart Failure*, **2018**, 20, 483-490	12.3	17
209	Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). *Maturitas*, **2018**, 108, 37-44	5	34
208	Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women. *Journal of the American Heart Association*, **2018**, 7, e009985	6	40
207	Sex Hormones and Change in N-Terminal Pro-B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of Atherosclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 4304-4314	5.6	25
206	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 320, 1764-1773	27.4	128

205	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2018**, 11, e005288	7.6	23
204	Fully Automated Echocardiogram Interpretation in Clinical Practice. *Circulation*, **2018**, 138, 1623-1635	16.7	287
203	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2018**, 11, e004540	7.6	18
202	New DEStiny Revealed: Young Woman Postablation for Wolf-Parkinson-White Syndrome With Recurrent Syncope and Progressive Myopathy. *Circulation*, **2018**, 138, 1267-1271	16.7	1
201	Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy. *Journal of the American Heart Association*, **2018**, 7, e09841	6	11
200	Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. *Journal of the American Heart Association*, **2018**, 7, e009594	6	44
199	Association of Patterns of Change in Adiposity With Diastolic Function and Systolic Myocardial Mechanics From Early Adulthood to Middle Age: The Coronary Artery Risk Development in Young Adults Study. *Journal of the American Society of Echocardiography*, **2018**, 31, 1261-1269.e8	5.8	10
198	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. *European Journal of Heart Failure*, **2018**,	12.3	20
197	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. *JAMA Cardiology*, **2018**, 3, 968-977	16.2	81
196	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2018**, 314, H1033-H1042	5.2	57
195	Endogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women. *Journal of the American College of Cardiology*, **2018**, 71, 2555-2566	15.1	143
194	Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. *Journal of Scleroderma and Related Disorders*, **2018**, 3, 159-169	2.3	11
193	Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease. *Clinical and Applied Thrombosis/Hemostasis*, **2017**, 23, 807-813	3.3	8
192	Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation. *Stem Cell Research*, **2017**, 18, 41-44	1.6	5
191	Generation of human iPSCs from urine derived cells of a non-affected control subject. *Stem Cell Research*, **2017**, 18, 33-36	1.6	4
190	Fine mapping of QT interval regions in global populations refines previously identified QT interval loci and identifies signals unique to African and Hispanic descent populations. *Heart Rhythm*, **2017**, 14, 572-580	6.7	15
189	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation: MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle). *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	9
188	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 399-409	4	11

187	Mode of Death in Heart Failure With Preserved Ejection Fraction. *Journal of the American College of Cardiology*, **2017**, 69, 556-569	15.1	135
186	Reduced haemodynamic coupling and exercise are associated with vascular stiffening in pulmonary arterial hypertension. *Heart*, **2017**, 103, 421-427	5.1	12
185	Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. *Journal of Cardiovascular Translational Research*, **2017**, 10, 275-284	3.3	37
184	Association of Albuminuria With Cardiac Dysfunction in US Hispanics/Latinos. *American Journal of Cardiology*, **2017**, 119, 2073-2080	3	4
183	RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes. *JACC: Cardiovascular Imaging*, **2017**, 10, 1211-1221	8.4	159
182	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1661-1670	10.2	38
181	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. *Circulation: Heart Failure*, **2017**, 10,	7.6	37
180	Prevalence and Predictors of Diastolic Dysfunction According to Different Classification Criteria: The Coronary Artery Risk Development in Young in Adults Study. *American Journal of Epidemiology*, **2017**, 185, 1221-1227	3.8	17
179	Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. *Vascular Medicine*, **2017**, 22, 218-224	3.3	2
178	Rasmussen-Torvik et al. Respond to "The Perfect Measure of Diastolic Dysfunction". *American Journal of Epidemiology*, **2017**, 185, 1231-1232	3.8	1
177	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circulation: Heart Failure*, **2017**, 10,	7.6	48
176	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. *Circulation: Heart Failure*, **2017**, 10,	7.6	18
175	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). *Circulation*, **2017**, 136, 982-992	16.7	55
174	Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. *European Journal of Heart Failure*, **2017**, 19, 782-791	12.3	54
173	Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials. *Journal of Cardiovascular Translational Research*, **2017**, 10, 313-321	3.3	25
172	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. *Journal of Cardiovascular Translational Research*, **2017**, 10, 233-244	3.3	40
171	Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups. *American Journal of Cardiology*, **2017**, 120, 601-606	3	10
170	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor- and Cardiac Fibrosis. *Circulation*, **2017**, 136, 664-679	16.7	40

169	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. *Bone Marrow Transplantation*, **2017**, 52, 1495-1503	4.4	62
168	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. *European Heart Journal*, **2017**, 38, 1119-1127	9.5	192
167	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2017**, 19, 1043-1052	12.3	22
166	Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction. *Journal of Cardiovascular Translational Research*, **2017**, 10, 305-312	3.3	21
165	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. *JACC: Heart Failure*, **2017**, 5, 241-252	7.9	90
164	Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. *Circulation: Heart Failure*, **2017**, 10,	7.6	11
163	A Test in Context: E/A and E/eO to Assess Diastolic Dysfunction and LV Filling Pressure. *Journal of the American College of Cardiology*, **2017**, 69, 1451-1464	15.1	132
162	Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. *Current Heart Failure Reports*, **2017**, 14, 519-528	2.8	30
161	Clinical characteristics of HIV-infected patients with adjudicated heart failure. *European Journal of Preventive Cardiology*, **2017**, 24, 1746-1758	3.9	19
160	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. *European Journal of Heart Failure*, **2017**, 19, 1690-1697	12.3	19
159	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. *JACC: Heart Failure*, **2017**, 5, 782-791	7.9	18
158	Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD. *International Journal of COPD*, **2017**, 12, 1439-1446	3	7
157	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. *European Journal of Heart Failure*, **2017**, 19, 1390-1400	12.3	111
156	Association of Estimated Sodium Intake With Adverse Cardiac Structure and Function: From the HyperGEN Study. *Journal of the American College of Cardiology*, **2017**, 70, 715-724	15.1	12
155	Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report. *ESC Heart Failure*, **2017**, 4, 645-648	3.7	6
154	A null mutation in protects against biological aging in humans. *Science Advances*, **2017**, 3, eaao1617	14.3	64
153	Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 2062-2068	9.5	15
152	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. *Journal of Cardiovascular Translational Research*, **2017**, 10, 322-336	3.3	27

151	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. *Current Heart Failure Reports*, **2017**, 14, 217-222	2.8	11
150	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. *Pharmacology & Therapeutics*, **2017**, 176, 32-39	13.9	35
149	Albuminuria, kidney function, and sudden cardiac death: Findings from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Heart Rhythm*, **2017**, 14, 65-71	6.7	6
148	GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals. *Scientific Reports*, **2017**, 7, 17075	4.9	8
147	Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. *Journal of Clinical Investigation*, **2017**, 127, 1798-1812	15.9	68
146	Cardiac Involvement: Evaluation and Management **2017**, 331-356		
145	Repolarization heterogeneity, diastolic dysfunction, and cardiovascular outcomes in heart failure with preserved ejection fraction. *International Journal of Cardiology*, **2016**, 223, 116-117	3.2	2
144	Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease. *Hypertension*, **2016**, 68, 913-20	8.5	21
143	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). *Circulation: Heart Failure*, **2016**, 9,	7.6	37
142	Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function: Results From ECHO-SOL (Echocardiographic Study of Latinos). *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	14
141	HIV-Related Myocardial Vulnerability to Infarction and Coronary Artery Disease. *Journal of the American College of Cardiology*, **2016**, 68, 2026-2027	15.1	15
140	Association of Central Adiposity With Adverse Cardiac Mechanics: Findings From the Hypertension Genetic Epidemiology Network Study. *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	42
139	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2016**, 9,	7.6	36
138	How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. *Current Cardiology Reports*, **2016**, 18, 122	4.2	19
137	Archeological Echocardiography: Digitization and Speckle Tracking Analysis of Archival Echocardiograms in the HyperGEN Study. *Echocardiography*, **2016**, 33, 386-97	1.5	17
136	Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?. *Current Heart Failure Reports*, **2016**, 13, 132-9	2.8	8
135	MR and CT Imaging for the Evaluation of Pulmonary Hypertension. *JACC: Cardiovascular Imaging*, **2016**, 9, 715-32	8.4	56
134	Constitutive Expression of a Dominant-Negative TGF- Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. *Circulation Research*, **2016**, 119, 69-82	15.7	28

133	Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. *Current Atherosclerosis Reports*, **2016**, 18, 48	6	9
132	Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. *Journal of Translational Medicine*, **2016**, 14, 18	8.5	13
131	Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. *Circulation: Heart Failure*, **2016**, 9,	7.6	133
130	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. *Circulation*, **2016**, 134, 73-90	16.7	485
129	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. *Heart Failure Reviews*, **2016**, 21, 455-62	5	21
128	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. *European Heart Journal*, **2016**, 37, 455-62	9.5	217
127	Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	177
126	Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. *Vascular Medicine*, **2016**, 21, 120-9	3.3	15
125	Comparison of Echocardiographic Measures in a Hispanic/Latino Population With the 2005 and 2015 American Society of Echocardiography Reference Limits (The Echocardiographic Study of Latinos). *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	10
124	Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?. *JACC: Heart Failure*, **2016**, 4, 93	7.9	
123	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. *Heart Failure Reviews*, **2016**, 21, 285-97	5	19
122	Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study. *Vascular Medicine*, **2016**, 21, 12-20	3.3	15
121	Interventional heart failure: a new field. *EuroIntervention*, **2016**, 12 Suppl X, X85-X88	3.1	2
120	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *Journal of the American College of Cardiology*, **2016**, 68, 161-72	15.1	215
119	Repolarization Heterogeneity: Beyond the QT Interval. *Journal of the American Heart Association*, **2016**, 5,	6	38
118	Pedal Edema as an Indicator of Early Heart Failure in the Community: Prevalence and Associations With Cardiac Structure/Function and Natriuretic Peptides (MESA [Multiethnic Study of Atherosclerosis]). *Circulation: Heart Failure*, **2016**, 9,	7.6	4
117	Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation. *Stem Cell Research*, **2016**, 17, 657-660	1.6	3
116	A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor?. *Journal of Thoracic and Cardiovascular Surgery*, **2016**, 151, 1288-97	1.5	11

115	Integrated analyses of gene expression and genetic association studies in a founder population. *Human Molecular Genetics*, **2016**, 25, 2104-2112	5.6	10
114	Burden of Systolic and Diastolic Left Ventricular Dysfunction Among Hispanics in the United States: Insights From the Echocardiographic Study of Latinos. *Circulation: Heart Failure*, **2016**, 9, e002733	7.6	29
113	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2016**, 9, e002763	7.6	147
112	Response to Letter Regarding Article, "Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate". *Circulation*, **2016**, 133, e431	16.7	
111	Impact of the Gather mHealth System on A1C: Primary Results of a Multisite Randomized Clinical Trial Among People With Type 2 Diabetes in India. *Diabetes Care*, **2016**, 39, e169-70	14.6	13
110	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. *European Journal of Heart Failure*, **2016**, 18, 54-65	12.3	57
109	Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. *European Journal of Heart Failure*, **2016**, 18, 103-12	12.3	103
108	Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. *Journal of Cardiac Failure*, **2015**, 21, 594-600	3.3	26
107	Association of 6-Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. *Journal of the American Heart Association*, **2015**, 4,	6	18
106	Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. *Circulation*, **2015**, 132, 278-91	16.7	138
105	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. *Circulation*, **2015**, 132, 402-14	16.7	263
104	Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. *JACC: Heart Failure*, **2015**, 3, 275-82	7.9	54
103	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-)gene and systemic sclerosis. *Arthritis Research and Therapy*, **2015**, 17, 128	5.7	21
102	Management of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2015**, 65, 1976-97	15.1	229
101	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*, **2015**, 373, 2314-24	59.2	331
100	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. *Circulation: Heart Failure*, **2015**, 8, 1052-8	7.6	54
99	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. *Current Atherosclerosis Reports*, **2015**, 17, 64	6	12
98	Association of Chronic Kidney Disease With Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction. *American Journal of Cardiology*, **2015**, 116, 1093-100	3	26

97	A non-invasive assessment of cardiopulmonary hemodynamics with MRI in pulmonary hypertension. *Magnetic Resonance Imaging*, **2015**, 33, 1224-1235	3.3	11
96	Favorable Levels of All Major Cardiovascular Risk Factors at Younger Ages and High-Sensitivity C-Reactive Protein 39 Years Later -The Chicago Healthy Aging Study. *Preventive Medicine Reports*, **2015**, 2, 235-240	2.6	7
95	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2251-62	27.4	188
94	Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation*, **2015**, 131, 269-79	16.7	499
93	Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. *Pulmonary Circulation*, **2015**, 5, 547-56	2.7	44
92	Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: results from two institutions. *Magnetic Resonance in Medicine*, **2015**, 73, 1904-13	4.4	94
91	Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. *Hepatology*, **2015**, 62, 773-83	11.2	157
90	Constrictive Pericarditis as a Cause of Refractory Ascites. *ACG Case Reports Journal*, **2015**, 2, 175-7	0.6	4
89	Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 76-85	10.2	36
88	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. *Circulation*, **2015**, 131, 34-42	16.7	534
87	Pulmonary hypertension secondary to heart failure with preserved ejection fraction. *Canadian Journal of Cardiology*, **2015**, 31, 430-9	3.8	21
86	Rationale and Design of the Echocardiographic Study of Hispanics/Latinos (ECHO-SOL). *Ethnicity and Disease*, **2015**, 25, 180-6	1.8	14
85	Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. *Current Cardiology Reviews*, **2015**, 11, 42-52	2.4	48
84	Spironolactone for heart failure with preserved ejection fraction. *New England Journal of Medicine*, **2014**, 370, 1383-92	59.2	1365
83	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. *JACC: Heart Failure*, **2014**, 2, 97-112	7.9	213
82	Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study. *Circulation*, **2014**, 129, 42-50	16.7	54
81	Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. *Current Cardiology Reports*, **2014**, 16, 545	4.2	22
80	Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H88-100	5.2	78

79	Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction. *Journal of the American Society of Echocardiography*, **2014**, 27, 74-82.e2	5.8	21
78	Relationship between repolarization heterogeneity and abnormal myocardial mechanics. *International Journal of Cardiology*, **2014**, 172, 289-91	3.2	14
77	Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation. *American Journal of Cardiology*, **2014**, 113, 2030-5	3	3
76	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. *American Heart Journal*, **2014**, 167, 853-60.e4	4.9	105
75	Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts. *Diabetes Care*, **2014**, 37, 372-80	14.6	13
74	Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. *Circulation: Heart Failure*, **2014**, 7, 288-99	7.6	139
73	Phenotypic spectrum of heart failure with preserved ejection fraction. *Heart Failure Clinics*, **2014**, 10, 407-18	3.3	86
72	Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2014**, 8, 187-95	8.9	10
71	Vulnerable blood in high risk vascular patients: study design and methods. *Contemporary Clinical Trials*, **2014**, 38, 121-9	2.3	11
70	Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). *European Journal of Heart Failure*, **2014**, 16, 1026-38	12.3	97
69	Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1 *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 314-24	10.2	154
68	Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. *Circulation: Heart Failure*, **2014**, 7, 104-15	7.6	174
67	Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. *JACC: Heart Failure*, **2014**, 2, 586-96	7.9	45
66	Association of comorbidity burden with abnormal cardiac mechanics: findings from the HyperGEN study. *Journal of the American Heart Association*, **2014**, 3, e000631	6	19
65	Diastolic wall strain: a simple marker of abnormal cardiac mechanics. *Cardiovascular Ultrasound*, **2014**, 12, 40	2.4	12
64	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. *Circulation: Heart Failure*, **2014**, 7, 740-51	7.6	159
63	Cardiac assessment before stem cell transplantation for systemic sclerosis. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1803	27.4	10
62	Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart failure. *Journal of Cardiac Failure*, **2014**, 20, 212-21	3.3	81

61	Abstract 15955: Widely Varying Prevalence of Diastolic Dysfunction by Different Classification Criteria: The Cardia Study. *Circulation*, **2014**, 130,	16.7	1
60	D-Dimer in the Months Leading up to Acute Coronary Events: A Case Crossover Study. *Blood*, **2014**, 124, 2864-2864	2.2	
59	The emerging epidemic of heart failure with preserved ejection fraction. *Current Heart Failure Reports*, **2013**, 10, 401-10	2.8	186
58	Relation of short-term heart rate variability to incident heart failure (from the Multi-Ethnic Study of Atherosclerosis). *American Journal of Cardiology*, **2013**, 112, 533-40	3	27
57	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. *American Journal of Cardiology*, **2013**, 112, 1158-64	3	62
56	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. *Lancet, The*, **2013**, 381, 1116-24	40	100
55	Echocardiography: Advanced Techniques (Tissue Doppler, Speckle Tracking, and Three-Dimensional Imaging) **2013**, 275-286		
54	Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 305, H1068-79	5.2	23
53	Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. *Circulation: Heart Failure*, **2013**, 6, 184-92	7.6	122
52	Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. *Journal of Investigative Dermatology*, **2013**, 133, 1979-89	4.3	102
51	Heart failure in North America. *Current Cardiology Reviews*, **2013**, 9, 128-46	2.4	44
50	Pulmonary hypertension. *JAMA - Journal of the American Medical Association*, **2012**, 308, 1366-74	27.4	57
49	Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. *American Journal of Cardiology*, **2012**, 110, 870-6	3	157
48	Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. *Journal of Heart and Lung Transplantation*, **2012**, 31, 467-77	5.8	34
47	Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. *American Journal of Cardiology*, **2012**, 110, 234-9	3	35
46	Diastolic electromechanical coupling: association of the ECG T-peak to T-end interval with echocardiographic markers of diastolic dysfunction. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 537-43	6.4	44
45	Polycystic ovary syndrome is associated with higher left ventricular mass index: the CARDIA women© study. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4656-62	5.6	28
44	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. *Clinical and Experimental Rheumatology*, **2012**, 30, S30-7	2.2	42

43	Cardiovascular risk assessment of the liver transplant candidate. *Journal of the American College of Cardiology*, **2011**, 58, 223-31	15.1	172
42	Phase II trials in heart failure: the role of cardiovascular imaging. *American Heart Journal*, **2011**, 162, 3-15.e3	4.3	6
41	Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. *Thrombosis Research*, **2011**, 128, 422-30	8.2	45
40	Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. *Lancet, The*, **2011**, 378, 498-506	40	330
39	Right heart structural changes are independently associated with exercise capacity in non-severe COPD. *PLoS ONE*, **2011**, 6, e29069	3.7	35
38	Systemic sclerosis and the heart: current diagnosis and management. *Current Opinion in Rheumatology*, **2011**, 23, 545-54	5.3	64
37	Limitations Inherent to the Simplified Bernoulli Equation Explain the Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension: Response. *Chest*, **2011**, 140, 270-271	5.3	5
36	Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. *American Journal of Cardiology*, **2011**, 108, 1760-6	3	47
35	Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. *Journal of Magnetic Resonance Imaging*, **2011**, 33, 225-31	5.6	25
34	Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circulation: Heart Failure*, **2011**, 4, 257-65	7.6	212
33	Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*, **2011**, 139, 988-993	5.3	260
32	MDCT bolus tracking data as an adjunct for predicting the diagnosis of pulmonary hypertension and concomitant right-heart failure. *American Journal of Roentgenology*, **2011**, 197, 1064-72	5.4	15
31	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2010**, 29, 181-7	5.8	45
30	Acute effects of intravenous nesiritide on cardiac contractility in heart failure. *Journal of Cardiac Failure*, **2010**, 16, 720-7	3.3	4
29	Evolving approaches to the management of heart failure with preserved ejection fraction in patients with coronary artery disease. *Current Treatment Options in Cardiovascular Medicine*, **2010**, 12, 58-75	2.1	24
28	From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 226-31	11.5	240
27	Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. *Circulation: Heart Failure*, **2009**, 2, 278-86	7.6	32
26	Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *American Journal of Cardiology*, **2009**, 104, 868-72	3	195

25	Genetics of systemic sclerosis-associated pulmonary arterial hypertension: recent progress and current concepts. *Current Rheumatology Reports*, **2009**, 11, 89-96	4.9	4
24	Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. *American Heart Journal*, **2009**, 157, 1035-41	4.9	99
23	Use of real time three-dimensional transesophageal echocardiography in intracardiac catheter based interventions. *Journal of the American Society of Echocardiography*, **2009**, 22, 865-82	5.8	128
22	Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. *Journal of the American Society of Echocardiography*, **2009**, 22, 190-7	5.8	60
21	Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. *Chest*, **2009**, 136, 694-700	5.3	38
20	Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. *Journal of the American College of Cardiology*, **2008**, 51, 1938-43	15.1	72
19	Heart failure with preserved ejection fraction: treat now by treating comorbidities. *JAMA - Journal of the American Medical Association*, **2008**, 300, 431-3	27.4	125
18	Association of the fourth heart sound with increased left ventricular end-diastolic stiffness. *Journal of Cardiac Failure*, **2008**, 14, 431-6	3.3	17
17	Physiology of the third heart sound: novel insights from tissue Doppler imaging. *Journal of the American Society of Echocardiography*, **2008**, 21, 394-400	5.8	16
16	Real-time three-dimensional transesophageal echocardiography of the left atrial appendage: initial experience in the clinical setting. *Journal of the American Society of Echocardiography*, **2008**, 21, 1362-8	5.8	91
15	Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. *Circulation*, **2008**, 117, 2475-83	16.7	93
14	C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. *European Journal of Heart Failure*, **2008**, 10, 63-9	12.3	50
13	Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients. *American Journal of Therapeutics*, **2008**, 15, 206-13	1	9
12	A distinguishing feature. *Journal of Hospital Medicine*, **2007**, 2, 39-45	2.7	0
11	Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). *American Journal of Cardiology*, **2007**, 99, 1128-33	3	28
10	Nesiritide: a reappraisal of efficacy and safety. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 361-9	4	7
9	Hemodynamic Correlates of the Third Heart Sound and Systolic Time Intervals. *Congestive Heart Failure*, **2006**, 12, 8-13		10
8	Hemodynamic correlates of the third heart sound and systolic time intervals. *Congestive Heart Failure*, **2006**, 12 Suppl 1, 8-13		21

7	High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. *Journal of Cardiac Failure*, **2006**, 12, 61-5	3.3	58
6	Cystic fibrosis transmembrane conductance regulator in human and mouse red blood cell membranes and its interaction with ecto-apyrase. *Journal of Cellular Biochemistry*, **2004**, 91, 1174-82	4.7	24
5	Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. *American Journal of Medicine*, **2004**, 117, 948-52	2.4	5
4	1H, 13C and 15N NMR assignments and solution secondary structure of rat Apo-S100 beta. *Journal of Biomolecular NMR*, **1995**, 6, 171-9	3	44
3	Artificial Intelligence-Enabled, Fully Automated Detection of Cardiac Amyloidosis Using Electrocardiograms and Echocardiograms		1
2	A Distinguishing Feature105-112		
1	Echocardiography: Standard Techniques (M-mode, Two-Dimensional Imaging, and Doppler)254-274		